| Date | Form | Description | Docs | XBRL | Pages |
| 10/02/13 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
60 | |
| 09/20/13 | 10-Q/A | Quarterly report pursuant to sections 13 or 15(d) |
|
|
3 |
| 09/16/13 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
66 | |
| 09/09/13 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 08/27/13 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 08/27/13 | DEF 14A | Definitive proxy statements |
|
36 | |
| 08/12/13 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
37 | |
| 07/16/13 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 07/16/13 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...